The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Higher Tocilizumab Dose Plus Methotrexate Best for Early RA

Higher Tocilizumab Dose Plus Methotrexate Best for Early RA

November 14, 2015 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Tocilizumab improves remission rates and slows disease progression in patients with early rheumatoid arthritis (RA), a new randomized controlled trial demonstrates.

You Might Also Like
  • Tocilizumab Plus Methotrexate Faster Fix in Some with RA
  • Tocilizumab Effectively Treats Early RA for Up to Two Years
  • Methotrexate with Step-Down Glucocorticoid Remission Induction Works in Early RA

Tocilizumab was effective both on its own and when combined with methotrexate, Dr. Gerd R. Burmester of Charite Medical University of Berlin and his colleagues found.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Tocilizumab, an interleukin-6 (IL-6) blocker, has been tested as a monotherapy and in combination with disease-modifying antirheumatic drugs (DMARDs) in RA patients, Dr. Burmester and colleagues note in their report, published online Oct. 28 in the Annals of the Rheumatic Diseases.

To investigate whether the drug might be effective in patients with early-stage, progressive RA, the researchers randomly assigned 1,162 methotrexate-naive patients to 4 mg/kg tocilizumab-methotrexate, 8 mg/kg tocilizumab-methotrexate, 8 mg/kg tocilizumab-placebo or placebo-methotrexate.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At Week 24, 45% of the 8 mg/kg tocilizumab-methotrexate group, 39% of the 8 mg/kg tocilizumab-placebo group, and 15% of the placebo-methotrexate had achieved remission (p<0.0001), defined as Disease Activity Score 28-erythrocyte sedimentation rate below 2.6.

By Week 52, patients on 8 mg/kg tocilizumab-methotrexate also had greater improvement in disease progression and function than patients who took placebo only.

Clinical efficacy with 8 mg/kg tocilizumab only and with 4 mg tocilizumab-methotrexate was at least equivalent to that of methotrexate for improving functions and symptoms and slowing joint damage.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“Our findings suggest that synergy between IL-6 inhibition and methotrexate action, rather than higher serum drug levels, drives the higher clinical response observed with (tocilizumab-methotrexate),” the researchers write.

“Although 8 mg/kg (tocilizumab-methotrexate) is the most effective treatment, both 4 mg/kg (tocilizumab-methotrexate) and 8 mg/kg (tocilizumab) monotherapy represent good alternative treatments for subsets of patients, such as those unable to tolerate (methotrexate) or the higher 8 mg/kg dose because of contraindications or adverse reactions,” they add.

The researchers plan to observe the patients for up to two years of blinded treatment to investigate outcomes and long-term safety in early RA patients.

Dr. Burmester was not available for an interview by press time.

Roche funded this research. Five coauthors reported relevant relationships.

Filed Under: Biologics & Biosimilars, Conditions, DMARDs & Immunosuppressives, Drug Updates, Rheumatoid Arthritis Tagged With: combination therapy, Methotrexate, Rheumatoid Arthritis (RA), tocilizumab

You Might Also Like:
  • Tocilizumab Plus Methotrexate Faster Fix in Some with RA
  • Tocilizumab Effectively Treats Early RA for Up to Two Years
  • Methotrexate with Step-Down Glucocorticoid Remission Induction Works in Early RA
  • Adding Prednisone to Methotrexate May Be Helpful in Early RA

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.